{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T05:03:39Z","timestamp":1792040619865,"version":"4.4.0"},"reference-count":139,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,1,4]]},"abstract":"<jats:p>Programmed cell death protein 1 (PD-1) blockade targeting the PD-1 immune checkpoint has demonstrated unprecedented clinical efficacy in the treatment of advanced cancers including hematologic malignancies. This article reviews the landscape of PD-1\/programmed death-ligand 1 (PD-L1) expression and current PD-1 blockade immunotherapy trials in B-cell lymphomas. Most notably, in relapsed\/refractory classical Hodgkin lymphoma, which frequently has increased PD-1+ tumor-infiltrating T cells, 9p24.1 genetic alteration, and high PD-L1 expression, anti-PD-1 monotherapy has demonstrated remarkable objective response rates (ORRs) of 65% to 87% and durable disease control in phase 1\/2 clinical trials. The median duration of response was 16 months in a phase 2 trial. PD-1 blockade has also shown promise in a phase 1 trial of nivolumab in relapsed\/refractory B-cell non-Hodgkin lymphomas, including follicular lymphoma, which often displays abundant PD-1 expression on intratumoral T cells, and diffuse large B-cell lymphoma, which variably expresses PD-1 and PD-L1. In primary mediastinal large B-cell lymphoma, which frequently has 9p24.1 alterations, the ORR was 35% in a phase 2 trial of pembrolizumab. In contrast, the ORR with pembrolizumab was 0% in relapsed chronic lymphocytic leukemia (CLL) and 44% in CLL with Richter transformation in a phase 2 trial. T cells from CLL patients have elevated PD-1 expression; CLL PD-1+ T cells can exhibit a pseudo-exhaustion or a replicative senescence phenotype. PD-1 expression was also found in marginal zone lymphoma but not in mantle cell lymphoma, although currently anti-PD-1 clinical trial data are not available. Mechanisms and predictive biomarkers for PD-1 blockade immunotherapy, treatment-related adverse events, hyperprogression, and combination therapies are discussed in the context of B-cell lymphomas.<\/jats:p>","DOI":"10.1182\/blood-2017-07-740993","type":"journal-article","created":{"date-parts":[[2017,11,8]],"date-time":"2017-11-08T15:25:13Z","timestamp":1510154713000},"page":"68-83","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":384,"title":["PD-1 expression and clinical PD-1 blockade in B-cell lymphomas"],"prefix":"10.1182","volume":"131","author":[{"given":"Zijun Y.","family":"Xu-Monette","sequence":"first","affiliation":[{"name":"Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfeng","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Hematology and Cancer Biology Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken H.","family":"Young","sequence":"additional","affiliation":[{"name":"Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX;"},{"name":"Graduate School of Biomedical Science, The University of Texas Health Science Center at Houston, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"11","key":"2019111822432367300_B1","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death","volume":"11","author":"Ishida","year":"1992","journal-title":"EMBO J"},{"issue":"7","key":"2019111822432367300_B2","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J Exp Med"},{"issue":"12","key":"2019111822432367300_B3","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1038\/70932","article-title":"B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion","volume":"5","author":"Dong","year":"1999","journal-title":"Nat Med"},{"issue":"3","key":"2019111822432367300_B4","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/85330","article-title":"PD-L2 is a second ligand for PD-1 and inhibits T cell activation","volume":"2","author":"Latchman","year":"2001","journal-title":"Nat Immunol"},{"issue":"1","key":"2019111822432367300_B5","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.immuni.2007.05.016","article-title":"Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses","volume":"27","author":"Butte","year":"2007","journal-title":"Immunity"},{"issue":"8","key":"2019111822432367300_B6","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1182\/blood-2010-01-265975","article-title":"B7-H1\/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance","volume":"116","author":"Park","year":"2010","journal-title":"Blood"},{"issue":"5","key":"2019111822432367300_B7","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1084\/jem.20130790","article-title":"RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance","volume":"211","author":"Xiao","year":"2014","journal-title":"J Exp Med"},{"issue":"7","key":"2019111822432367300_B8","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1172\/JCI85796","article-title":"Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality","volume":"126","author":"Saha","year":"2016","journal-title":"J Clin Invest"},{"issue":"5","key":"2019111822432367300_B9","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1172\/JCI91138","article-title":"PD-L1 interacts with CD80 to regulate graft-versus-leukemia activity of donor CD8+ T cells","volume":"127","author":"Ni","year":"2017","journal-title":"J Clin Invest"},{"issue":"11","key":"2019111822432367300_B10","doi-asserted-by":"crossref","first-page":"5606","DOI":"10.4049\/jimmunol.1003976","article-title":"B7-h1 expressed by activated CD8 T cells is essential for their survival","volume":"187","author":"Pulko","year":"2011","journal-title":"J Immunol"},{"issue":"3","key":"2019111822432367300_B11","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1172\/JCI16015","article-title":"Costimulating aberrant T cell responses by B7-H1 autoantibodies in rheumatoid arthritis","volume":"111","author":"Dong","year":"2003","journal-title":"J Clin Invest"},{"issue":"1","key":"2019111822432367300_B12","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1084\/jem.20030242","article-title":"Cooperative B7-1\/2 (CD80\/CD86) and B7-DC costimulation of CD4+ T cells independent of the PD-1 receptor","volume":"198","author":"Shin","year":"2003","journal-title":"J Exp Med"},{"issue":"7","key":"2019111822432367300_B13","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1084\/jem.193.7.839","article-title":"B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells","volume":"193","author":"Tseng","year":"2001","journal-title":"J Exp Med"},{"issue":"9","key":"2019111822432367300_B14","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1084\/jem.20021752","article-title":"Molecular modeling and functional mapping of B7-H1 and B7-DC uncouple costimulatory function from PD-1 interaction","volume":"197","author":"Wang","year":"2003","journal-title":"J Exp Med"},{"issue":"12","key":"2019111822432367300_B15","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1084\/jem.20022089","article-title":"B7DC\/PDL2 promotes tumor immunity by a PD-1-independent mechanism","volume":"197","author":"Liu","year":"2003","journal-title":"J Exp Med"},{"issue":"2","key":"2019111822432367300_B16","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.imlet.2005.09.007","article-title":"Co-inhibitory role of T-cell-associated B7-H1 and B7-DC in the T-cell immune response","volume":"102","author":"Seo","year":"2006","journal-title":"Immunol Lett"},{"issue":"9","key":"2019111822432367300_B17","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1182\/blood-2005-08-3376","article-title":"Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma","volume":"107","author":"Yang","year":"2006","journal-title":"Blood"},{"issue":"5","key":"2019111822432367300_B18","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.immuni.2011.03.014","article-title":"B7-h2 is a costimulatory ligand for CD28 in human","volume":"34","author":"Yao","year":"2011","journal-title":"Immunity"},{"issue":"29","key":"2019111822432367300_B19","doi-asserted-by":"crossref","first-page":"10691","DOI":"10.1073\/pnas.0307252101","article-title":"PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells","volume":"101","author":"Latchman","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"2019111822432367300_B20","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"issue":"31","key":"2019111822432367300_B21","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1200\/JCO.2016.67.3467","article-title":"Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure","volume":"34","author":"Armand","year":"2017","journal-title":"J Clin Oncol"},{"issue":"9","key":"2019111822432367300_B22","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin\u2019s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol"},{"issue":"19","key":"2019111822432367300_B23","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J Clin Oncol"},{"issue":"7463","key":"2019111822432367300_B24","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"issue":"17","key":"2019111822432367300_B25","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"issue":"4","key":"2019111822432367300_B26","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1084\/jem.184.4.1495","article-title":"Hodgkin and Reed-Sternberg cells in Hodgkin\u2019s disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells","volume":"184","author":"Kanzler","year":"1996","journal-title":"J Exp Med"},{"issue":"23","key":"2019111822432367300_B27","doi-asserted-by":"crossref","first-page":"10962","DOI":"10.1073\/pnas.91.23.10962","article-title":"Hodgkin disease: Hodgkin and Reed-Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development","volume":"91","author":"K\u00fcppers","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"2019111822432367300_B28","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1158\/2326-6066.CIR-14-0040","article-title":"In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates","volume":"2","author":"Wang","year":"2014","journal-title":"Cancer Immunol Res"},{"issue":"6","key":"2019111822432367300_B29","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/sj.leu.2400683","article-title":"Expression of B7-2 (CD86) molecules by Reed-Sternberg cells of Hodgkin\u2019s disease","volume":"11","author":"Van Gool","year":"1997","journal-title":"Leukemia"},{"issue":"1","key":"2019111822432367300_B30","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1440-1827.1998.tb03821.x","article-title":"Costimulatory molecules (CD80 and CD86) on Reed-Sternberg cells are associated with the proliferation of background T cells in Hodgkin\u2019s disease","volume":"48","author":"Nozawa","year":"1998","journal-title":"Pathol Int"},{"issue":"12","key":"2019111822432367300_B31","doi-asserted-by":"crossref","first-page":"3332","DOI":"10.1002\/eji.1830251220","article-title":"Malignant B lymphocytes from non-Hodgkin\u2019s lymphoma induce allogeneic proliferative and cytotoxic T cell responses in primary mixed lymphocyte cultures: an important role of co-stimulatory molecules CD80 (B7-1) and CD86 (B7-2) in stimulation by tumor cells","volume":"25","author":"Plumas","year":"1995","journal-title":"Eur J Immunol"},{"issue":"2","key":"2019111822432367300_B32","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/cyto.b.20631","article-title":"CD80 (B7.1) is expressed on both malignant B cells and nonmalignant stromal cells in non-Hodgkin lymphoma","volume":"82","author":"Dakappagari","year":"2012","journal-title":"Cytometry B Clin Cytom"},{"issue":"4","key":"2019111822432367300_B33","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1046\/j.1365-2567.1998.00550.x","article-title":"Localization in situ of costimulatory molecules and cytokines in B-cell non-Hodgkin\u2019s lymphoma","volume":"94","author":"Vyth-Dreese","year":"1998","journal-title":"Immunology"},{"issue":"11","key":"2019111822432367300_B34","doi-asserted-by":"crossref","first-page":"4297","DOI":"10.1182\/blood.V90.11.4297","article-title":"In vivo expression of B7-1 and B7-2 by follicular lymphoma cells can prevent induction of T-cell anergy but is insufficient to induce significant T-cell proliferation","volume":"90","author":"Dorfman","year":"1997","journal-title":"Blood"},{"issue":"3","key":"2019111822432367300_B35","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0301-472X(98)00059-9","article-title":"Functional expression of CD80 and CD86 allows immunogenicity of malignant B cells from non-Hodgkin\u2019s lymphomas","volume":"27","author":"Chaperot","year":"1999","journal-title":"Exp Hematol"},{"issue":"11","key":"2019111822432367300_B36","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1158\/2326-6066.CIR-16-0201","article-title":"Classical Hodgkin lymphoma with reduced \u03b22M\/MHC class I expression is associated with inferior outcome independent of 9p24.1 status","volume":"4","author":"Roemer","year":"2016","journal-title":"Cancer Immunol Res"},{"issue":"4","key":"2019111822432367300_B37","doi-asserted-by":"crossref","first-page":"e1295202","DOI":"10.1080\/2162402X.2017.1295202","article-title":"HLA dependent immune escape mechanisms in B-cell lymphomas: Implications for immune checkpoint inhibitor therapy?","volume":"6","author":"Nijland","year":"2017","journal-title":"OncoImmunology"},{"issue":"2","key":"2019111822432367300_B38","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1046\/j.1365-2141.2002.03814.x","article-title":"Major histocompatibility complex abnormalities in non-Hodgkin lymphomas","volume":"119","author":"Dr\u00e9nou","year":"2002","journal-title":"Br J Haematol"},{"issue":"3","key":"2019111822432367300_B39","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/sj.leu.2403240","article-title":"Prognostic significance of activated cytotoxic T-lymphocytes in primary nodal diffuse large B-cell lymphomas","volume":"18","author":"Muris","year":"2004","journal-title":"Leukemia"},{"issue":"6","key":"2019111822432367300_B40","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.ccr.2011.11.006","article-title":"Combined genetic inactivation of \u03b22-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma","volume":"20","author":"Challa-Malladi","year":"2011","journal-title":"Cancer Cell"},{"issue":"6","key":"2019111822432367300_B41","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1182\/blood-2007-05-085159","article-title":"PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma","volume":"111","author":"Yamamoto","year":"2008","journal-title":"Blood"},{"issue":"12","key":"2019111822432367300_B42","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/j.humpath.2009.03.025","article-title":"Increased programmed death-1+ tumor-infiltrating lymphocytes in classical Hodgkin lymphoma substantiate reduced overall survival","volume":"40","author":"Muenst","year":"2009","journal-title":"Hum Pathol"},{"issue":"7","key":"2019111822432367300_B43","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1097\/01.pas.0000209855.28282.ce","article-title":"Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma","volume":"30","author":"Dorfman","year":"2006","journal-title":"Am J Surg Pathol"},{"issue":"8","key":"2019111822432367300_B44","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1038\/modpathol.2009.54","article-title":"Lymphocyte-rich classical Hodgkin\u2019s lymphoma: distinctive tumor and microenvironment markers","volume":"22","author":"Nam-Cha","year":"2009","journal-title":"Mod Pathol"},{"issue":"16","key":"2019111822432367300_B45","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1182\/blood-2013-06-508044","article-title":"Defining characteristics of classical Hodgkin lymphoma microenvironment T-helper cells","volume":"122","author":"Greaves","year":"2013","journal-title":"Blood"},{"issue":"1","key":"2019111822432367300_B46","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1155\/2010\/404069","article-title":"Diagnostic and prognostic utility of PD-1 in B cell lymphomas","volume":"29","author":"Muenst","year":"2010","journal-title":"Dis Markers"},{"issue":"9","key":"2019111822432367300_B47","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.2008.18.0513","article-title":"High numbers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma","volume":"27","author":"Carreras","year":"2009","journal-title":"J Clin Oncol"},{"issue":"8","key":"2019111822432367300_B48","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2012-04-421826","article-title":"High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells","volume":"121","author":"Myklebust","year":"2013","journal-title":"Blood"},{"issue":"2","key":"2019111822432367300_B49","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1158\/1078-0432.CCR-09-2487","article-title":"A unifying microenvironment model in follicular lymphoma: outcome is predicted by programmed death-1--positive, regulatory, cytotoxic, and helper T cells and macrophages","volume":"16","author":"Wahlin","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"11","key":"2019111822432367300_B50","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1158\/1078-0432.CCR-13-2367","article-title":"Pattern of CD14+ follicular dendritic cells and PD1+ T cells independently predicts time to transformation in follicular lymphoma","volume":"20","author":"Smeltzer","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2019111822432367300_B51","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.humpath.2010.08.015","article-title":"Follicular programmed death 1-positive lymphocytes in the tumor microenvironment are an independent prognostic factor in follicular lymphoma","volume":"42","author":"Richendollar","year":"2011","journal-title":"Hum Pathol"},{"key":"2019111822432367300_B52","author":"Yang","year":"2015"},{"issue":"7","key":"2019111822432367300_B53","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1182\/blood-2012-02-411678","article-title":"Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer","volume":"120","author":"Ramsay","year":"2012","journal-title":"Blood"},{"issue":"1","key":"2019111822432367300_B54","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/bjh.14201","article-title":"The tumour microenvironment influences survival and time to transformation in follicular lymphoma in the rituximab era","volume":"175","author":"Blaker","year":"2016","journal-title":"Br J Haematol"},{"issue":"4","key":"2019111822432367300_B55","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/ejh.12075","article-title":"Prognostic significance of programmed cell death-1-positive cells in follicular lymphoma patients may alter in the rituximab era","volume":"90","author":"Takahashi","year":"2013","journal-title":"Eur J Haematol"},{"issue":"3","key":"2019111822432367300_B56","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00428-014-1615-5","article-title":"Expression of PD-1 (CD279) and FoxP3 in diffuse large B-cell lymphoma","volume":"465","author":"Ahearne","year":"2014","journal-title":"Virchows Arch"},{"issue":"19","key":"2019111822432367300_B57","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1182\/blood-2015-02-629600","article-title":"Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma","volume":"126","author":"Kiyasu","year":"2015","journal-title":"Blood"},{"issue":"7","key":"2019111822432367300_B58","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/his.12882","article-title":"Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas","volume":"68","author":"Kwon","year":"2016","journal-title":"Histopathology"},{"issue":"15","key":"2019111822432367300_B59","doi-asserted-by":"crossref","first-page":"e6398","DOI":"10.1097\/MD.0000000000006398","article-title":"The expression and clinical relevance of PD-1, PD-L1, and TP63 in patients with diffuse large B-cell lymphoma","volume":"96","author":"Fang","year":"2017","journal-title":"Medicine (Baltimore)"},{"issue":"8","key":"2019111822432367300_B60","doi-asserted-by":"crossref","first-page":"e1026530","DOI":"10.1080\/2162402X.2015.1026530","article-title":"Several immune escape patterns in non-Hodgkin\u2019s lymphomas","volume":"4","author":"Laurent","year":"2015","journal-title":"OncoImmunology"},{"key":"2019111822432367300_B61","author":"Menter"},{"key":"2019111822432367300_B62","article-title":"CD274 (PD-L1)\/PDCD1 (PD-1) expression in de novo and transformed diffuse large B-cell lymphoma [published online ahead of print 23 November 2016]","author":"Kwiecinska","journal-title":"Br J Haematol"},{"issue":"1","key":"2019111822432367300_B63","doi-asserted-by":"crossref","first-page":"10813","DOI":"10.1038\/s41598-017-11052-z","article-title":"Cytotoxic response against Epstein Barr virus coexists with diffuse large B-cell lymphoma tolerogenic microenvironment: clinical features and survival impact","volume":"7","author":"Cohen","year":"2017","journal-title":"Sci Rep"},{"key":"2019111822432367300_B64","author":"Zhang","year":"2015"},{"issue":"11","key":"2019111822432367300_B65","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1002\/cam4.874","article-title":"PD-1 expression on the surface of peripheral blood CD4(+) T cell and its association with the prognosis of patients with diffuse large B-cell lymphoma","volume":"5","author":"Zhang","year":"2016","journal-title":"Cancer Med"},{"issue":"6","key":"2019111822432367300_B66","doi-asserted-by":"crossref","first-page":"953","DOI":"10.3324\/haematol.2012.077537","article-title":"The PD-1\/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia","volume":"98","author":"Brusa","year":"2013","journal-title":"Haematologica"},{"issue":"9","key":"2019111822432367300_B67","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1182\/blood-2012-09-457531","article-title":"T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production","volume":"121","author":"Riches","year":"2013","journal-title":"Blood"},{"issue":"10","key":"2019111822432367300_B68","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.3109\/10428194.2015.1017820","article-title":"The function of a novel immunophenotype candidate molecule PD-1 in chronic lymphocytic leukemia","volume":"56","author":"Grzywnowicz","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"2019111822432367300_B69","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1158\/1078-0432.CCR-11-2630","article-title":"Expansion of a CD8(+)PD-1(+) replicative senescence phenotype in early stage CLL patients is associated with inverted CD4:CD8 ratios and disease progression","volume":"18","author":"Nunes","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2019111822432367300_B70","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1182\/blood-2013-08-518183","article-title":"CMV-specific CD8+ T-cell function is not impaired in chronic lymphocytic leukemia","volume":"123","author":"te Raa","year":"2014","journal-title":"Blood"},{"issue":"9","key":"2019111822432367300_B71","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.3109\/10428194.2012.673224","article-title":"Expansion of effector T cells associated with decreased PD-1 expression in patients with indolent B cell lymphomas and chronic lymphocytic leukemia","volume":"53","author":"Tonino","year":"2012","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2019111822432367300_B72","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/cup.12440","article-title":"PD-1, S-100 and CD1a expression in pseudolymphomatous folliculitis, primary cutaneous marginal zone B-cell lymphoma (MALT lymphoma) and cutaneous lymphoid hyperplasia","volume":"42","author":"Goyal","year":"2015","journal-title":"J Cutan Pathol"},{"issue":"1","key":"2019111822432367300_B73","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/cup.12254","article-title":"Programmed death-1 expression in cutaneous B-cell lymphoma","volume":"41","author":"\u00c7etin\u00f6zman","year":"2014","journal-title":"J Cutan Pathol"},{"issue":"7","key":"2019111822432367300_B74","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.humpath.2007.11.012","article-title":"Programmed death 1 is a marker of angioimmunoblastic T-cell lymphoma and B-cell small lymphocytic lymphoma\/chronic lymphocytic leukemia","volume":"39","author":"Xerri","year":"2008","journal-title":"Hum Pathol"},{"issue":"4","key":"2019111822432367300_B75","doi-asserted-by":"crossref","first-page":"e35178","DOI":"10.1371\/journal.pone.0035178","article-title":"Programmed death-1 and its ligand are novel immunotolerant molecules expressed on leukemic B cells in chronic lymphocytic leukemia","volume":"7","author":"Grzywnowicz","year":"2012","journal-title":"PLoS One"},{"issue":"26","key":"2019111822432367300_B76","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1182\/blood-2017-02-765685","article-title":"Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL","volume":"129","author":"Ding","year":"2017","journal-title":"Blood"},{"issue":"24","key":"2019111822432367300_B77","doi-asserted-by":"crossref","first-page":"13866","DOI":"10.1073\/pnas.231486598","article-title":"PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine","volume":"98","author":"Okazaki","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"2019111822432367300_B78","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/intimm\/dxs098","article-title":"PD-1 is a novel regulator of human B-cell activation","volume":"25","author":"Thibult","year":"2013","journal-title":"Int Immunol"},{"issue":"10","key":"2019111822432367300_B79","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.3324\/haematol.2016.145904","article-title":"Catching up with solid tumor oncology: what is the evidence for a prognostic role of programmed cell death-ligand 1\/programmed cell death-1 expression in B-cell lymphomas?","volume":"101","author":"McClanahan","year":"2016","journal-title":"Haematologica"},{"issue":"2","key":"2019111822432367300_B80","doi-asserted-by":"crossref","first-page":"945","DOI":"10.4049\/jimmunol.173.2.945","article-title":"SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation","volume":"173","author":"Chemnitz","year":"2004","journal-title":"J Immunol"},{"issue":"6","key":"2019111822432367300_B81","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1084\/jem.20031074","article-title":"Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma","volume":"198","author":"Rosenwald","year":"2003","journal-title":"J Exp Med"},{"issue":"12","key":"2019111822432367300_B82","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1097\/PAS.0000000000000297","article-title":"Expression of programmed cell death 1 ligand 2 (PD-L2) is a distinguishing feature of primary mediastinal (thymic) large B-cell lymphoma and associated with PDCD1LG2 copy gain","volume":"38","author":"Shi","year":"2014","journal-title":"Am J Surg Pathol"},{"issue":"13","key":"2019111822432367300_B83","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1158\/1078-0432.CCR-13-0855","article-title":"PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies","volume":"19","author":"Chen","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"23","key":"2019111822432367300_B84","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome","volume":"34","author":"Roemer","year":"2016","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111822432367300_B85","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1182\/blood-2009-12-257345","article-title":"Genome-wide copy number analysis of Hodgkin Reed-Sternberg cells identifies recurrent imbalances with correlations to treatment outcome","volume":"116","author":"Steidl","year":"2010","journal-title":"Blood"},{"issue":"6","key":"2019111822432367300_B86","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1158\/1078-0432.CCR-11-1942","article-title":"Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy","volume":"18","author":"Green","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"13","key":"2019111822432367300_B87","doi-asserted-by":"crossref","first-page":"4232","DOI":"10.1158\/1078-0432.CCR-10-2660","article-title":"Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells","volume":"17","author":"Andorsky","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"24","key":"2019111822432367300_B88","doi-asserted-by":"crossref","first-page":"3026","DOI":"10.1182\/blood-2015-12-686550","article-title":"Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas","volume":"127","author":"Georgiou","year":"2016","journal-title":"Blood"},{"issue":"12","key":"2019111822432367300_B89","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1038\/leu.2014.137","article-title":"High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial","volume":"28","author":"Rossille","year":"2014","journal-title":"Leukemia"},{"issue":"4","key":"2019111822432367300_B90","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/leu.2016.385","article-title":"Soluble programmed death-ligand 1 as a prognostic biomarker for overall survival in patients with diffuse large B-cell lymphoma: a replication study and combined analysis of 508 patients","volume":"31","author":"Rossille","year":"2017","journal-title":"Leukemia"},{"issue":"7","key":"2019111822432367300_B91","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1182\/blood-2015-10-673236","article-title":"Targetable genetic features of primary testicular and primary central nervous system lymphomas","volume":"127","author":"Chapuy","year":"2016","journal-title":"Blood"},{"issue":"7607","key":"2019111822432367300_B92","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/nature18294","article-title":"Aberrant PD-L1 expression through 3\u2032-UTR disruption in multiple cancers","volume":"534","author":"Kataoka","year":"2016","journal-title":"Nature"},{"issue":"9","key":"2019111822432367300_B93","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1158\/1078-0432.CCR-13-3157","article-title":"Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries","volume":"20","author":"Ok","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2019111822432367300_B94","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1111\/bjh.13085","article-title":"CD30 expression in de novo diffuse large B-cell lymphoma: a population-based study from British Columbia","volume":"167","author":"Slack","year":"2014","journal-title":"Br J Haematol"},{"issue":"10","key":"2019111822432367300_B95","doi-asserted-by":"crossref","first-page":"e445","DOI":"10.1016\/S2352-3026(15)00150-7","article-title":"Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study","volume":"2","author":"Keane","year":"2015","journal-title":"Lancet Haematol"},{"issue":"13","key":"2019111822432367300_B96","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1182\/blood-2013-10-535443","article-title":"Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma","volume":"123","author":"Twa","year":"2014","journal-title":"Blood"},{"issue":"7338","key":"2019111822432367300_B97","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/nature09754","article-title":"MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers","volume":"471","author":"Steidl","year":"2011","journal-title":"Nature"},{"issue":"1","key":"2019111822432367300_B98","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1182\/blood-2005-11-4742","article-title":"Loss of major histocompatibility class II gene and protein expression in primary mediastinal large B-cell lymphoma is highly coordinated and related to poor patient survival","volume":"108","author":"Roberts","year":"2006","journal-title":"Blood"},{"issue":"9","key":"2019111822432367300_B99","doi-asserted-by":"crossref","first-page":"e0136476","DOI":"10.1371\/journal.pone.0136476","article-title":"PD-1 blockade can restore functions of T-cells in Epstein-Barr virus-positive diffuse large B-cell lymphoma in vitro","volume":"10","author":"Quan","year":"2015","journal-title":"PLoS One"},{"issue":"6","key":"2019111822432367300_B100","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.4049\/jimmunol.1502464","article-title":"Suppression of Glut1 and Glucose Metabolism by Decreased Akt\/mTORC1 Signaling Drives T Cell Impairment in B Cell Leukemia","volume":"197","author":"Siska","year":"2016","journal-title":"J Immunol"},{"issue":"2","key":"2019111822432367300_B101","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1182\/blood-2015-01-622936","article-title":"PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia","volume":"126","author":"McClanahan","year":"2015","journal-title":"Blood"},{"key":"2019111822432367300_B102","author":"Lee","year":"2016"},{"key":"2019111822432367300_B103","author":"Tan","year":"2017"},{"issue":"10","key":"2019111822432367300_B104","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1158\/1078-0432.CCR-07-4079","article-title":"Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies","volume":"14","author":"Berger","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"33","key":"2019111822432367300_B105","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.1200\/JCO.2012.48.3685","article-title":"Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial","volume":"31","author":"Armand","year":"2013","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111822432367300_B106","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S1470-2045(13)70551-5","article-title":"Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial","volume":"15","author":"Westin","year":"2014","journal-title":"Lancet Oncol"},{"issue":"23","key":"2019111822432367300_B107","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: Preliminary results of a phase Ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J Clin Oncol"},{"issue":"22","key":"2019111822432367300_B108","article-title":"A phase 1 study of nivolumab in combination with ipilimumab for relapsed or refractory hematologic malignancies (CheckMate 039)","volume":"128","author":"Ansell","year":"2016","journal-title":"Blood"},{"issue":"3","key":"2019111822432367300_B109","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1182\/blood-2016-12-758383","article-title":"Safety and tolerability of pembrolizumab in patients with relapsed\/refractory primary mediastinal large B-cell lymphoma","volume":"130","author":"Zinzani","year":"2017","journal-title":"Blood"},{"issue":"23","key":"2019111822432367300_B110","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1182\/blood-2017-01-764209","article-title":"PD-1 blockade with nivolumab in relapsed\/refractory primary central nervous system and testicular lymphoma","volume":"129","author":"Nayak","year":"2017","journal-title":"Blood"},{"issue":"22","key":"2019111822432367300_B111","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.59.59","article-title":"Nivolumab combined with ibrutinib for CLL and Richter transformation: a phase II trial [abstract]","volume":"128","author":"Jain","year":"2016","journal-title":"Blood"},{"key":"2019111822432367300_B112","author":"Nastoupil","year":"2017"},{"issue":"Supplement S2","key":"2019111822432367300_B113","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/hon.2437_72","article-title":"Safety and efficacy of combination of brentuximab vedotin and nivolumab in relapsed\/refractory Hodgkin lymphoma: A trial of the ECOG-ACRIN Cancer Research Group (E4412)","volume":"35","author":"Diefenbach","year":"2017","journal-title":"Hematol Oncol"},{"issue":"Supplement S2","key":"2019111822432367300_B114","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/hon.2437_73","article-title":"Interim results from a phase 1\/2 study of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma","volume":"35","author":"Herrera","year":"2017","journal-title":"Hematol Oncol"},{"issue":"Supplement S2","key":"2019111822432367300_B115","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/hon.2437_49","article-title":"Efficacy and safety of pembrolizumab in relapsed\/refractory primary mediastinal large B-cell lymphoma (rrPMBCL): interim analysis of the KEYNOTE-170 phase 2 trial","volume":"35","author":"Zinzani","year":"2017","journal-title":"Hematol Oncol"},{"issue":"5","key":"2019111822432367300_B116","doi-asserted-by":"crossref","first-page":"e1005642","DOI":"10.1371\/journal.ppat.1005642","article-title":"PD-1\/CTLA-4 blockade inhibits Epstein-Barr virus-induced lymphoma growth in a cord blood humanized-mouse model","volume":"12","author":"Ma","year":"2016","journal-title":"PLoS Pathog"},{"issue":"8","key":"2019111822432367300_B117","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1038\/cr.2017.90","article-title":"Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function","volume":"27","author":"Lee","year":"2017","journal-title":"Cell Res"},{"issue":"10","key":"2019111822432367300_B118","doi-asserted-by":"crossref","first-page":"e1224044","DOI":"10.1080\/2162402X.2016.1224044","article-title":"Impaired functional responses in follicular lymphoma CD8(+)TIM-3(+) T lymphocytes following TCR engagement","volume":"5","author":"Gravelle","year":"2016","journal-title":"OncoImmunology"},{"issue":"18","key":"2019111822432367300_B119","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1182\/blood-2016-11-749556","article-title":"Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma","volume":"129","author":"Herbaux","year":"2017","journal-title":"Blood"},{"key":"2019111822432367300_B120","article-title":"Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1\/PD-L1","author":"Champiat","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"15","key":"2019111822432367300_B121","doi-asserted-by":"crossref","first-page":"4242","DOI":"10.1158\/1078-0432.CCR-16-3133","article-title":"Hyperprogressors after immunotherapy: Analysis of genomic alterations associated with accelerated growth rate","volume":"23","author":"Kato","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2019111822432367300_B122","doi-asserted-by":"crossref","first-page":"711","DOI":"10.4049\/jimmunol.170.2.711","article-title":"Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses","volume":"170","author":"Bennett","year":"2003","journal-title":"J Immunol"},{"issue":"10","key":"2019111822432367300_B123","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/emmm.201100165","article-title":"PD-L1 co-stimulation contributes to ligand-induced T cell receptor down-modulation on CD8+ T cells","volume":"3","author":"Karwacz","year":"2011","journal-title":"EMBO Mol Med"},{"issue":"1","key":"2019111822432367300_B124","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nri3790","article-title":"Clinical blockade of PD1 and LAG3--potential mechanisms of action","volume":"15","author":"Nguyen","year":"2015","journal-title":"Nat Rev Immunol"},{"issue":"8","key":"2019111822432367300_B125","doi-asserted-by":"crossref","first-page":"e1202391","DOI":"10.1080\/2162402X.2016.1202391","article-title":"PD-L1 peptide co-stimulation increases immunogenicity of a dendritic cell-based cancer vaccine","volume":"5","author":"Munir Ahmad","year":"2016","journal-title":"OncoImmunology"},{"issue":"5","key":"2019111822432367300_B126","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1172\/JCI19210","article-title":"Local expression of B7-H1 promotes organ-specific autoimmunity and transplant rejection","volume":"113","author":"Subudhi","year":"2004","journal-title":"J Clin Invest"},{"issue":"6","key":"2019111822432367300_B127","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1182\/blood-2004-09-3458","article-title":"NK cells that are activated by CXCL10 can kill dormant tumor cells that resist CTL-mediated lysis and can express B7-H1 that stimulates T cells","volume":"105","author":"Saudemont","year":"2005","journal-title":"Blood"},{"issue":"6","key":"2019111822432367300_B128","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood.V97.6.1809","article-title":"B7-H1 costimulation preferentially enhances CD28-independent T-helper cell function","volume":"97","author":"Tamura","year":"2001","journal-title":"Blood"},{"issue":"8","key":"2019111822432367300_B129","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1073\/pnas.0813367106","article-title":"B7-H1 (PD-L1) on T cells is required for T-cell-mediated conditioning of dendritic cell maturation","volume":"106","author":"Talay","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"2019111822432367300_B130","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1053\/j.gastro.2008.05.076","article-title":"B7-H1 on hepatocytes facilitates priming of specific CD8 T cells but limits the specific recall of primed responses","volume":"135","author":"Wahl","year":"2008","journal-title":"Gastroenterology"},{"issue":"8","key":"2019111822432367300_B131","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1093\/intimm\/dxq049","article-title":"PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1","volume":"22","author":"Ghiotto","year":"2010","journal-title":"Int Immunol"},{"issue":"3","key":"2019111822432367300_B132","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.4049\/jimmunol.170.3.1257","article-title":"Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production","volume":"170","author":"Brown","year":"2003","journal-title":"J Immunol"},{"issue":"26","key":"2019111822432367300_B133","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"issue":"7","key":"2019111822432367300_B134","first-page":"656","volume":"7","year":"2017","journal-title":"Cancer Discov"},{"issue":"11","key":"2019111822432367300_B135","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1111\/j.1349-7006.2009.01302.x","article-title":"B7-H1 expression is regulated by MEK\/ERK signaling pathway in anaplastic large cell lymphoma and Hodgkin lymphoma","volume":"100","author":"Yamamoto","year":"2009","journal-title":"Cancer Sci"},{"issue":"1","key":"2019111822432367300_B136","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.immuni.2005.05.005","article-title":"Oscillating CD8(+) T cell effector functions after antigen recognition in the liver","volume":"23","author":"Isogawa","year":"2005","journal-title":"Immunity"},{"issue":"7655","key":"2019111822432367300_B137","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/nature22367","article-title":"Chromatin states define tumour-specific T cell dysfunction and reprogramming","volume":"545","author":"Philip","year":"2017","journal-title":"Nature"},{"issue":"3","key":"2019111822432367300_B138","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1182\/blood.V83.3.793.793","article-title":"In vivo expression of the B7 costimulatory molecule by subsets of antigen-presenting cells and the malignant cells of Hodgkin\u2019s disease","volume":"83","author":"Munro","year":"1994","journal-title":"Blood"},{"issue":"9","key":"2019111822432367300_B139","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1182\/blood.V82.9.2845.2845","article-title":"The B7\/BB1 antigen is expressed by Reed-Sternberg cells of Hodgkin\u2019s disease and contributes to the stimulating capacity of Hodgkin\u2019s disease-derived cell lines","volume":"82","author":"Delabie","year":"1993","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/131\/1\/68\/1368156\/blood740993.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/131\/1\/68\/1368156\/blood740993.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T22:44:10Z","timestamp":1574117050000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/131\/1\/68\/107727\/PD1-expression-and-clinical-PD1-blockade-in-Bcell"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,4]]},"references-count":139,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1,4]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2017-07-740993","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.732096524.793554323","asserted-by":"object"}]},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,4]]}}}